ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 000368

Role of Nitric Oxide in Motor Control: Implications for Parkinson's Disease Pathophysiology and Treatment

Identifieur interne : 000368 ( PascalFrancis/Corpus ); précédent : 000367; suivant : 000369

Role of Nitric Oxide in Motor Control: Implications for Parkinson's Disease Pathophysiology and Treatment

Auteurs : Elaine Del-Bel ; Fernando Eduardo Padovan-Neto ; Rita Raisman-Vozarl ; Marcio Lazzarini

Source :

Current pharmaceutical design : (Print) [ 1381-6128 ] ; 2011.

RBID : Pascal:11-0416725

Descripteurs français

Pascal (Inist)
- Monoxyde d'azote, Contrôle moteur, Maladie de Parkinson, Physiopathologie, Traitement, Inhibiteur de la NO synthase, Dopamine, Animal, Souris, Lévodopa, Dyskinésie, Mouvement anormal, Mouvement involontaire, Article synthèse.

English descriptors

KwdEn :
- Abnormal movement, Animal, Dopamine, Dyskinesia, Involuntary movement, Levodopa, Motor control, Mouse, Nitric oxide, Nitric oxide synthase inhibitor, Parkinson disease, Pathophysiology, Review, Treatment.

Abstract

According to classical thinking about Parkinson's disease, loss of dopaminergic input from the substantia nigra pars compacta leads to overactivity and underactivity of the indirect and direct output pathways, respectively, in the basal ganglia. Administration of the dopamine precursor L-DOPA (1-3, 4-dihydroxyphenylalanine) is proposed to induce changes in the opposite directions. L-DOPA is the most used drug to treat Parkinson's disease symptoms. After repeated treatment with this compound, however, disabling secondary effects such as the abnormal involuntary movements usually appear. Nitric oxide is a free radical that can also acts as an atypical neurotransmitter and influences dopamine-mediated neurotransmission. In this paper we will briefly review the role of nitric oxide on motor control and in Parkinson's disease, particularly a possible role of nitric oxide in L-DOPA induced dyskinesia in rodents. Recent results show that nitric oxide synthase inhibition reduces L-DOPA-induced dyskinesia in rats and mice. The effect is dose-dependent, does not suffer tolerance nor interferes with L-DOPA positive motor effects. These preclinical findings suggest that nitric oxide is a promising therapeutic target for the reduction of L-DOPA-induced dyskinesia.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1381-6128`
A03		`1`		`@0 Curr. pharm. des. : (Print)`
A05				`@2 17`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Role of Nitric Oxide in Motor Control: Implications for Parkinson's Disease Pathophysiology and Treatment`
A09	`01`	`1`	`ENG`	`@1 Novel Therapeutic Strategies in Neural Diseases Uncover Unexpected Disease Connections: From Neurodegeneration and Addiction to Pain and Depression`
A11	`01`	`1`		`@1 DEL-BEL (Elaine)`
A11	`02`	`1`		`@1 PADOVAN-NETO (Fernando Eduardo)`
A11	`03`	`1`		`@1 RAISMAN-VOZARL (Rita)`
A11	`04`	`1`		`@1 LAZZARINI (Marcio)`
A12	`01`	`1`		`@1 HERRADON (Gonzalo) @9 ed.`
A14	`01`			`@1 Medical School, Department of Behavioural Neuroscience, (FMRP-USP) @3 FRA @Z 1 aut. @Z 2 aut. @Z 4 aut.`
A14	`02`			`@1 Dentistry School, Department of Physiology, (FORP-USP) @3 FRA @Z 1 aut. @Z 2 aut. @Z 4 aut.`
A14	`03`			`@1 Inserm, UMR 975, CRICM, ICM, Thérapeutique Expérimental de la Neurodégénérescence @3 FRA @Z 3 aut.`
A14	`04`			`@1 Université Pierre & Marie Curie-Paris, Faculté de Médecine @3 FRA @Z 3 aut.`
A14	`05`			`@1 CNRS, UMR 7225 @2 Paris, 75013 @3 FRA @Z 3 aut.`
A15	`01`			`@1 Department of Pharmaceutical and Food Sciences, Faculty of Pharmacy, University San Pablo CEU @2 Madrid @3 ESP @Z 1 aut.`
A20				`@1 471-488`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 26320 @5 354000189800790060`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 228 ref.`
A47	`01`	`1`		`@0 11-0416725`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Current pharmaceutical design : (Print)`
A66	`01`			`@0 ARE`
C01	`01`		`ENG`	@0 According to classical thinking about Parkinson's disease, loss of dopaminergic input from the substantia nigra pars compacta leads to overactivity and underactivity of the indirect and direct output pathways, respectively, in the basal ganglia. Administration of the dopamine precursor L-DOPA (1-3, 4-dihydroxyphenylalanine) is proposed to induce changes in the opposite directions. L-DOPA is the most used drug to treat Parkinson's disease symptoms. After repeated treatment with this compound, however, disabling secondary effects such as the abnormal involuntary movements usually appear. Nitric oxide is a free radical that can also acts as an atypical neurotransmitter and influences dopamine-mediated neurotransmission. In this paper we will briefly review the role of nitric oxide on motor control and in Parkinson's disease, particularly a possible role of nitric oxide in L-DOPA induced dyskinesia in rodents. Recent results show that nitric oxide synthase inhibition reduces L-DOPA-induced dyskinesia in rats and mice. The effect is dose-dependent, does not suffer tolerance nor interferes with L-DOPA positive motor effects. These preclinical findings suggest that nitric oxide is a promising therapeutic target for the reduction of L-DOPA-induced dyskinesia.
C02	`01`	`X`		`@0 002B17G`
C02	`02`	`X`		`@0 002B17A01`
C02	`03`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Monoxyde d'azote @2 NK @2 FX @5 01`
C03	`01`	`X`	`ENG`	`@0 Nitric oxide @2 NK @2 FX @5 01`
C03	`01`	`X`	`SPA`	`@0 Nitrógeno monóxido @2 NK @2 FX @5 01`
C03	`02`	`X`	`FRE`	`@0 Contrôle moteur @5 02`
C03	`02`	`X`	`ENG`	`@0 Motor control @5 02`
C03	`02`	`X`	`SPA`	`@0 Control motor @5 02`
C03	`03`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Physiopathologie @5 04`
C03	`04`	`X`	`ENG`	`@0 Pathophysiology @5 04`
C03	`04`	`X`	`SPA`	`@0 Fisiopatología @5 04`
C03	`05`	`X`	`FRE`	`@0 Traitement @5 05`
C03	`05`	`X`	`ENG`	`@0 Treatment @5 05`
C03	`05`	`X`	`SPA`	`@0 Tratamiento @5 05`
C03	`06`	`X`	`FRE`	`@0 Inhibiteur de la NO synthase @5 07`
C03	`06`	`X`	`ENG`	`@0 Nitric oxide synthase inhibitor @5 07`
C03	`06`	`X`	`SPA`	`@0 Inhibidor NO synthase @5 07`
C03	`07`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 08`
C03	`07`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 08`
C03	`07`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 08`
C03	`08`	`X`	`FRE`	`@0 Animal @5 09`
C03	`08`	`X`	`ENG`	`@0 Animal @5 09`
C03	`08`	`X`	`SPA`	`@0 Animal @5 09`
C03	`09`	`X`	`FRE`	`@0 Souris @5 10`
C03	`09`	`X`	`ENG`	`@0 Mouse @5 10`
C03	`09`	`X`	`SPA`	`@0 Ratón @5 10`
C03	`10`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 11`
C03	`10`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 11`
C03	`10`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 11`
C03	`11`	`X`	`FRE`	`@0 Dyskinésie @5 12`
C03	`11`	`X`	`ENG`	`@0 Dyskinesia @5 12`
C03	`11`	`X`	`SPA`	`@0 Disquinesia @5 12`
C03	`12`	`X`	`FRE`	`@0 Mouvement anormal @5 13`
C03	`12`	`X`	`ENG`	`@0 Abnormal movement @5 13`
C03	`12`	`X`	`SPA`	`@0 Movimiento anormal @5 13`
C03	`13`	`X`	`FRE`	`@0 Mouvement involontaire @5 14`
C03	`13`	`X`	`ENG`	`@0 Involuntary movement @5 14`
C03	`13`	`X`	`SPA`	`@0 Movimiento involuntario @5 14`
C03	`14`	`X`	`FRE`	`@0 Article synthèse @5 15`
C03	`14`	`X`	`ENG`	`@0 Review @5 15`
C03	`14`	`X`	`SPA`	`@0 Artículo síntesis @5 15`
C07	`01`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`02`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 37`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 37`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 37`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 38`
C07	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 38`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 38`
C07	`06`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 39`
C07	`06`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`06`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`07`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 40`
C07	`07`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`07`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`08`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 41`
C07	`08`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`08`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
C07	`09`	`X`	`FRE`	`@0 Catécholamine @5 42`
C07	`09`	`X`	`ENG`	`@0 Catecholamine @5 42`
C07	`09`	`X`	`SPA`	`@0 Catecolamina @5 42`
C07	`10`	`X`	`FRE`	`@0 Neurotransmetteur @5 43`
C07	`10`	`X`	`ENG`	`@0 Neurotransmitter @5 43`
C07	`10`	`X`	`SPA`	`@0 Neurotransmisor @5 43`
C07	`11`	`X`	`FRE`	`@0 Agoniste @5 44`
C07	`11`	`X`	`ENG`	`@0 Agonist @5 44`
C07	`11`	`X`	`SPA`	`@0 Agonista @5 44`
C07	`12`	`X`	`FRE`	`@0 Récepteur dopaminergique D2 @5 45`
C07	`12`	`X`	`ENG`	`@0 D2 Dopamine receptor @5 45`
C07	`12`	`X`	`SPA`	`@0 Receptor dopaminérgico D2 @5 45`
C07	`13`	`X`	`FRE`	`@0 Antiparkinsonien @5 46`
C07	`13`	`X`	`ENG`	`@0 Antiparkinson agent @5 46`
C07	`13`	`X`	`SPA`	`@0 Antiparkinsoniano @5 46`
C07	`14`	`X`	`FRE`	`@0 Trouble neurologique @5 47`
C07	`14`	`X`	`ENG`	`@0 Neurological disorder @5 47`
C07	`14`	`X`	`SPA`	`@0 Trastorno neurológico @5 47`
N21				`@1 283`

Format Inist (serveur)

NO :	PASCAL 11-0416725 INIST
ET :	Role of Nitric Oxide in Motor Control: Implications for Parkinson's Disease Pathophysiology and Treatment
AU :	DEL-BEL (Elaine); PADOVAN-NETO (Fernando Eduardo); RAISMAN-VOZARL (Rita); LAZZARINI (Marcio); HERRADON (Gonzalo)
AF :	Medical School, Department of Behavioural Neuroscience, (FMRP-USP)/France (1 aut., 2 aut., 4 aut.); Dentistry School, Department of Physiology, (FORP-USP)/France (1 aut., 2 aut., 4 aut.); Inserm, UMR 975, CRICM, ICM, Thérapeutique Expérimental de la Neurodégénérescence/France (3 aut.); Université Pierre & Marie Curie-Paris, Faculté de Médecine/France (3 aut.); CNRS, UMR 7225/Paris, 75013/France (3 aut.); Department of Pharmaceutical and Food Sciences, Faculty of Pharmacy, University San Pablo CEU/Madrid/Espagne (1 aut.)
DT :	Publication en série; Niveau analytique
SO :	Current pharmaceutical design : (Print); ISSN 1381-6128; Emirats Arabes Unis; Da. 2011; Vol. 17; No. 5; Pp. 471-488; Bibl. 228 ref.
LA :	Anglais
EA :	According to classical thinking about Parkinson's disease, loss of dopaminergic input from the substantia nigra pars compacta leads to overactivity and underactivity of the indirect and direct output pathways, respectively, in the basal ganglia. Administration of the dopamine precursor L-DOPA (1-3, 4-dihydroxyphenylalanine) is proposed to induce changes in the opposite directions. L-DOPA is the most used drug to treat Parkinson's disease symptoms. After repeated treatment with this compound, however, disabling secondary effects such as the abnormal involuntary movements usually appear. Nitric oxide is a free radical that can also acts as an atypical neurotransmitter and influences dopamine-mediated neurotransmission. In this paper we will briefly review the role of nitric oxide on motor control and in Parkinson's disease, particularly a possible role of nitric oxide in L-DOPA induced dyskinesia in rodents. Recent results show that nitric oxide synthase inhibition reduces L-DOPA-induced dyskinesia in rats and mice. The effect is dose-dependent, does not suffer tolerance nor interferes with L-DOPA positive motor effects. These preclinical findings suggest that nitric oxide is a promising therapeutic target for the reduction of L-DOPA-induced dyskinesia.
CC :	002B17G; 002B17A01; 002B02B06
FD :	Monoxyde d'azote; Contrôle moteur; Maladie de Parkinson; Physiopathologie; Traitement; Inhibiteur de la NO synthase; Dopamine; Animal; Souris; Lévodopa; Dyskinésie; Mouvement anormal; Mouvement involontaire; Article synthèse
FG :	Rodentia; Mammalia; Vertebrata; Maladie dégénérative; Pathologie du système nerveux; Pathologie de l'encéphale; Syndrome extrapyramidal; Pathologie du système nerveux central; Catécholamine; Neurotransmetteur; Agoniste; Récepteur dopaminergique D2; Antiparkinsonien; Trouble neurologique
ED :	Nitric oxide; Motor control; Parkinson disease; Pathophysiology; Treatment; Nitric oxide synthase inhibitor; Dopamine; Animal; Mouse; Levodopa; Dyskinesia; Abnormal movement; Involuntary movement; Review
EG :	Rodentia; Mammalia; Vertebrata; Degenerative disease; Nervous system diseases; Cerebral disorder; Extrapyramidal syndrome; Central nervous system disease; Catecholamine; Neurotransmitter; Agonist; D2 Dopamine receptor; Antiparkinson agent; Neurological disorder
SD :	Nitrógeno monóxido; Control motor; Parkinson enfermedad; Fisiopatología; Tratamiento; Inhibidor NO synthase; Dopamina; Animal; Ratón; Levodopa; Disquinesia; Movimiento anormal; Movimiento involuntario; Artículo síntesis
LO :	INIST-26320.354000189800790060
ID :	11-0416725

Links to Exploration step

Pascal:11-0416725

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Role of Nitric Oxide in Motor Control: Implications for Parkinson's Disease Pathophysiology and Treatment</title>
<author><name sortKey="Del Bel, Elaine" sort="Del Bel, Elaine" uniqKey="Del Bel E" first="Elaine" last="Del-Bel">Elaine Del-Bel</name>
<affiliation><inist:fA14 i1="01"><s1>Medical School, Department of Behavioural Neuroscience, (FMRP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Dentistry School, Department of Physiology, (FORP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Padovan Neto, Fernando Eduardo" sort="Padovan Neto, Fernando Eduardo" uniqKey="Padovan Neto F" first="Fernando Eduardo" last="Padovan-Neto">Fernando Eduardo Padovan-Neto</name>
<affiliation><inist:fA14 i1="01"><s1>Medical School, Department of Behavioural Neuroscience, (FMRP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Dentistry School, Department of Physiology, (FORP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Raisman Vozarl, Rita" sort="Raisman Vozarl, Rita" uniqKey="Raisman Vozarl R" first="Rita" last="Raisman-Vozarl">Rita Raisman-Vozarl</name>
<affiliation><inist:fA14 i1="03"><s1>Inserm, UMR 975, CRICM, ICM, Thérapeutique Expérimental de la Neurodégénérescence</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Université Pierre & Marie Curie-Paris, Faculté de Médecine</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>CNRS, UMR 7225</s1>
<s2>Paris, 75013</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lazzarini, Marcio" sort="Lazzarini, Marcio" uniqKey="Lazzarini M" first="Marcio" last="Lazzarini">Marcio Lazzarini</name>
<affiliation><inist:fA14 i1="01"><s1>Medical School, Department of Behavioural Neuroscience, (FMRP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Dentistry School, Department of Physiology, (FORP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0416725</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0416725 INIST</idno>
<idno type="RBID">Pascal:11-0416725</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000368</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Role of Nitric Oxide in Motor Control: Implications for Parkinson's Disease Pathophysiology and Treatment</title>
<author><name sortKey="Del Bel, Elaine" sort="Del Bel, Elaine" uniqKey="Del Bel E" first="Elaine" last="Del-Bel">Elaine Del-Bel</name>
<affiliation><inist:fA14 i1="01"><s1>Medical School, Department of Behavioural Neuroscience, (FMRP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Dentistry School, Department of Physiology, (FORP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Padovan Neto, Fernando Eduardo" sort="Padovan Neto, Fernando Eduardo" uniqKey="Padovan Neto F" first="Fernando Eduardo" last="Padovan-Neto">Fernando Eduardo Padovan-Neto</name>
<affiliation><inist:fA14 i1="01"><s1>Medical School, Department of Behavioural Neuroscience, (FMRP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Dentistry School, Department of Physiology, (FORP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Raisman Vozarl, Rita" sort="Raisman Vozarl, Rita" uniqKey="Raisman Vozarl R" first="Rita" last="Raisman-Vozarl">Rita Raisman-Vozarl</name>
<affiliation><inist:fA14 i1="03"><s1>Inserm, UMR 975, CRICM, ICM, Thérapeutique Expérimental de la Neurodégénérescence</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Université Pierre & Marie Curie-Paris, Faculté de Médecine</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>CNRS, UMR 7225</s1>
<s2>Paris, 75013</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lazzarini, Marcio" sort="Lazzarini, Marcio" uniqKey="Lazzarini M" first="Marcio" last="Lazzarini">Marcio Lazzarini</name>
<affiliation><inist:fA14 i1="01"><s1>Medical School, Department of Behavioural Neuroscience, (FMRP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Dentistry School, Department of Physiology, (FORP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Current pharmaceutical design : (Print)</title>
<title level="j" type="abbreviated">Curr. pharm. des. : (Print)</title>
<idno type="ISSN">1381-6128</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Current pharmaceutical design : (Print)</title>
<title level="j" type="abbreviated">Curr. pharm. des. : (Print)</title>
<idno type="ISSN">1381-6128</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abnormal movement</term>
<term>Animal</term>
<term>Dopamine</term>
<term>Dyskinesia</term>
<term>Involuntary movement</term>
<term>Levodopa</term>
<term>Motor control</term>
<term>Mouse</term>
<term>Nitric oxide</term>
<term>Nitric oxide synthase inhibitor</term>
<term>Parkinson disease</term>
<term>Pathophysiology</term>
<term>Review</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Monoxyde d'azote</term>
<term>Contrôle moteur</term>
<term>Maladie de Parkinson</term>
<term>Physiopathologie</term>
<term>Traitement</term>
<term>Inhibiteur de la NO synthase</term>
<term>Dopamine</term>
<term>Animal</term>
<term>Souris</term>
<term>Lévodopa</term>
<term>Dyskinésie</term>
<term>Mouvement anormal</term>
<term>Mouvement involontaire</term>
<term>Article synthèse</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">According to classical thinking about Parkinson's disease, loss of dopaminergic input from the substantia nigra pars compacta leads to overactivity and underactivity of the indirect and direct output pathways, respectively, in the basal ganglia. Administration of the dopamine precursor L-DOPA (1-3, 4-dihydroxyphenylalanine) is proposed to induce changes in the opposite directions. L-DOPA is the most used drug to treat Parkinson's disease symptoms. After repeated treatment with this compound, however, disabling secondary effects such as the abnormal involuntary movements usually appear. Nitric oxide is a free radical that can also acts as an atypical neurotransmitter and influences dopamine-mediated neurotransmission. In this paper we will briefly review the role of nitric oxide on motor control and in Parkinson's disease, particularly a possible role of nitric oxide in L-DOPA induced dyskinesia in rodents. Recent results show that nitric oxide synthase inhibition reduces L-DOPA-induced dyskinesia in rats and mice. The effect is dose-dependent, does not suffer tolerance nor interferes with L-DOPA positive motor effects. These preclinical findings suggest that nitric oxide is a promising therapeutic target for the reduction of L-DOPA-induced dyskinesia.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1381-6128</s0>
</fA01>
<fA03 i2="1"><s0>Curr. pharm. des. : (Print)</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Role of Nitric Oxide in Motor Control: Implications for Parkinson's Disease Pathophysiology and Treatment</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Novel Therapeutic Strategies in Neural Diseases Uncover Unexpected Disease Connections: From Neurodegeneration and Addiction to Pain and Depression</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>DEL-BEL (Elaine)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>PADOVAN-NETO (Fernando Eduardo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>RAISMAN-VOZARL (Rita)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LAZZARINI (Marcio)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>HERRADON (Gonzalo)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Medical School, Department of Behavioural Neuroscience, (FMRP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Dentistry School, Department of Physiology, (FORP-USP)</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Inserm, UMR 975, CRICM, ICM, Thérapeutique Expérimental de la Neurodégénérescence</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Université Pierre & Marie Curie-Paris, Faculté de Médecine</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>CNRS, UMR 7225</s1>
<s2>Paris, 75013</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Department of Pharmaceutical and Food Sciences, Faculty of Pharmacy, University San Pablo CEU</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA20><s1>471-488</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26320</s2>
<s5>354000189800790060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>228 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0416725</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Current pharmaceutical design : (Print)</s0>
</fA64>
<fA66 i1="01"><s0>ARE</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>According to classical thinking about Parkinson's disease, loss of dopaminergic input from the substantia nigra pars compacta leads to overactivity and underactivity of the indirect and direct output pathways, respectively, in the basal ganglia. Administration of the dopamine precursor L-DOPA (1-3, 4-dihydroxyphenylalanine) is proposed to induce changes in the opposite directions. L-DOPA is the most used drug to treat Parkinson's disease symptoms. After repeated treatment with this compound, however, disabling secondary effects such as the abnormal involuntary movements usually appear. Nitric oxide is a free radical that can also acts as an atypical neurotransmitter and influences dopamine-mediated neurotransmission. In this paper we will briefly review the role of nitric oxide on motor control and in Parkinson's disease, particularly a possible role of nitric oxide in L-DOPA induced dyskinesia in rodents. Recent results show that nitric oxide synthase inhibition reduces L-DOPA-induced dyskinesia in rats and mice. The effect is dose-dependent, does not suffer tolerance nor interferes with L-DOPA positive motor effects. These preclinical findings suggest that nitric oxide is a promising therapeutic target for the reduction of L-DOPA-induced dyskinesia.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17A01</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Monoxyde d'azote</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nitric oxide</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Nitrógeno monóxido</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Contrôle moteur</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Motor control</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Control motor</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Physiopathologie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Pathophysiology</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Fisiopatología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Inhibiteur de la NO synthase</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Nitric oxide synthase inhibitor</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Inhibidor NO synthase</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Animal</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Animal</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Animal</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Souris</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Mouse</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Ratón</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Mouvement anormal</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Abnormal movement</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Movimiento anormal</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>15</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Review</s0>
<s5>15</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>15</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>42</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>43</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>44</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Agonist</s0>
<s5>44</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Agonista</s0>
<s5>44</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>45</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>45</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>45</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>46</s5>
</fC07>
<fC07 i1="13" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>46</s5>
</fC07>
<fC07 i1="13" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>46</s5>
</fC07>
<fC07 i1="14" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>47</s5>
</fC07>
<fC07 i1="14" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>47</s5>
</fC07>
<fC07 i1="14" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>47</s5>
</fC07>
<fN21><s1>283</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 11-0416725 INIST</NO>
<ET>Role of Nitric Oxide in Motor Control: Implications for Parkinson's Disease Pathophysiology and Treatment</ET>
<AU>DEL-BEL (Elaine); PADOVAN-NETO (Fernando Eduardo); RAISMAN-VOZARL (Rita); LAZZARINI (Marcio); HERRADON (Gonzalo)</AU>
<AF>Medical School, Department of Behavioural Neuroscience, (FMRP-USP)/France (1 aut., 2 aut., 4 aut.); Dentistry School, Department of Physiology, (FORP-USP)/France (1 aut., 2 aut., 4 aut.); Inserm, UMR 975, CRICM, ICM, Thérapeutique Expérimental de la Neurodégénérescence/France (3 aut.); Université Pierre & Marie Curie-Paris, Faculté de Médecine/France (3 aut.); CNRS, UMR 7225/Paris, 75013/France (3 aut.); Department of Pharmaceutical and Food Sciences, Faculty of Pharmacy, University San Pablo CEU/Madrid/Espagne (1 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Current pharmaceutical design : (Print); ISSN 1381-6128; Emirats Arabes Unis; Da. 2011; Vol. 17; No. 5; Pp. 471-488; Bibl. 228 ref.</SO>
<LA>Anglais</LA>
<EA>According to classical thinking about Parkinson's disease, loss of dopaminergic input from the substantia nigra pars compacta leads to overactivity and underactivity of the indirect and direct output pathways, respectively, in the basal ganglia. Administration of the dopamine precursor L-DOPA (1-3, 4-dihydroxyphenylalanine) is proposed to induce changes in the opposite directions. L-DOPA is the most used drug to treat Parkinson's disease symptoms. After repeated treatment with this compound, however, disabling secondary effects such as the abnormal involuntary movements usually appear. Nitric oxide is a free radical that can also acts as an atypical neurotransmitter and influences dopamine-mediated neurotransmission. In this paper we will briefly review the role of nitric oxide on motor control and in Parkinson's disease, particularly a possible role of nitric oxide in L-DOPA induced dyskinesia in rodents. Recent results show that nitric oxide synthase inhibition reduces L-DOPA-induced dyskinesia in rats and mice. The effect is dose-dependent, does not suffer tolerance nor interferes with L-DOPA positive motor effects. These preclinical findings suggest that nitric oxide is a promising therapeutic target for the reduction of L-DOPA-induced dyskinesia.</EA>
<CC>002B17G; 002B17A01; 002B02B06</CC>
<FD>Monoxyde d'azote; Contrôle moteur; Maladie de Parkinson; Physiopathologie; Traitement; Inhibiteur de la NO synthase; Dopamine; Animal; Souris; Lévodopa; Dyskinésie; Mouvement anormal; Mouvement involontaire; Article synthèse</FD>
<FG>Rodentia; Mammalia; Vertebrata; Maladie dégénérative; Pathologie du   système nerveux; Pathologie de l'encéphale; Syndrome extrapyramidal; Pathologie du   système nerveux central; Catécholamine; Neurotransmetteur; Agoniste; Récepteur dopaminergique D2; Antiparkinsonien; Trouble neurologique</FG>
<ED>Nitric oxide; Motor control; Parkinson disease; Pathophysiology; Treatment; Nitric oxide synthase inhibitor; Dopamine; Animal; Mouse; Levodopa; Dyskinesia; Abnormal movement; Involuntary movement; Review</ED>
<EG>Rodentia; Mammalia; Vertebrata; Degenerative disease; Nervous system diseases; Cerebral disorder; Extrapyramidal syndrome; Central nervous system disease; Catecholamine; Neurotransmitter; Agonist; D2 Dopamine receptor; Antiparkinson agent; Neurological disorder</EG>
<SD>Nitrógeno monóxido; Control motor; Parkinson enfermedad; Fisiopatología; Tratamiento; Inhibidor NO synthase; Dopamina; Animal; Ratón; Levodopa; Disquinesia; Movimiento anormal; Movimiento involuntario; Artículo síntesis</SD>
<LO>INIST-26320.354000189800790060</LO>
<ID>11-0416725</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000368 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000368 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0416725
   |texte=   Role of Nitric Oxide in Motor Control: Implications for Parkinson's Disease Pathophysiology and Treatment
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Role of Nitric Oxide in Motor Control: Implications for Parkinson's Disease Pathophysiology and Treatment

Role of Nitric Oxide in Motor Control: Implications for Parkinson's Disease Pathophysiology and Treatment

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri